The new CRP titled ‘Mesenchymal stem cell based regenerative medicine technologies for treatment of radiation induced lesions,’ will explore the potential of adult MSCT to address the complex challenge of radiation-induced lesions.
“Regenerative medicine — particularly adult MSCT — has the potential to improve healing and restore quality of life for those affected,” said May Abdel-Wahab, Director of the IAEA Division of Human Health. “This project represents a major step forward in the effort to alleviate suffering and deliver transformative care for individuals living with untoward consequences of radiation exposure.”
Jean-Jacques Lataillade, Director of the Armed Forces Blood Transfusion Centre at the French Defence Health Service, who contributed to the development of the project, said: “Mesenchymal stem cells represent a promising modality in regenerative medicine, attributed to their inherent ability to migrate to damaged tissues, modulate immune and inflammatory responses, promote cell survival and tissue repair, as well as stimulate angiogenesis.”